GSK banks on monoclonal antibodies
Reporter: Aviva Lev-Ari, PhD, RN
GlaxoSmithKline is partnering up with Canadian biotherapeutics maker Zymeworks Inc. in order to develop Fc-engineered monoclonal and bi-specific antibody therapies.
Sourced through Scoop.it from: www.european-biotechnology-news.com
Leave a Reply